Myfortic (Mycophenolic Acid)

Mycophenolic acid, the active ingredient in Myfortic, is an immunosuppressant presented as a delayed‑release oral tablet for oral use. It prevents organ transplant rejection in adult patients receiving solid‑organ grafts.

GNH USA supplies Myfortic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Myfortic, an antimetabolite immunosuppressant, is used in solid‑organ transplantation to reduce immune‑mediated graft rejection.

- Kidney transplant: lowers the risk of acute and chronic rejection. - Heart transplant: helps maintain graft function by suppressing lymphocyte proliferation. - Liver transplant: supports long‑term graft survival through immune modulation.

Myfortic may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: watery stools often occurring early in therapy. - Abdominal pain: cramping or discomfort in the stomach area. - Headache: transient tension‑type headaches. - Tremor: fine shaking of the hands or limbs. - Upper respiratory infection: mild cold‑like symptoms.

Serious or Rare Side Effects: - Leukopenia: significant reduction in white blood cells increasing infection risk. - Anemia: decreased red blood cell count leading to fatigue. - Severe infection: opportunistic infections requiring prompt medical attention. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Malignancy: increased long‑term risk of certain cancers. - Progressive multifocal leukoencephalopathy: rare but potentially fatal brain infection.

Before initiating Myfortic, clinicians should consider several safety measures.

- Blood count monitoring: perform regular CBC to detect leukopenia or anemia. - Renal function assessment: adjust dosing in patients with impaired kidney function. - Live vaccine avoidance: do not administer live attenuated vaccines during therapy. - Pregnancy counseling: discuss potential risks and advise effective contraception. - Drug interaction review: evaluate concomitant immunosuppressants for additive effects. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Myfortic can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Azathioprine: additive bone‑marrow suppression may cause severe cytopenias. - Cyclosporine: increased mycophenolic acid exposure can heighten toxicity. - Tacrolimus: combined immunosuppression raises infection risk.

Moderate Interactions (Monitor Closely): - Rifampin: induces metabolism, reducing mycophenolic acid levels. - Antacids containing aluminum or magnesium: decrease absorption of the delayed‑release tablet. - Cholestyramine: binds drug in the gut, lowering systemic exposure.